GSA Capital Partners LLP Grows Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

GSA Capital Partners LLP raised its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 791.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 57,985 shares of the company’s stock after purchasing an additional 51,482 shares during the period. GSA Capital Partners LLP’s holdings in Mirum Pharmaceuticals were worth $2,261,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in MIRM. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Mirum Pharmaceuticals by 7.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,641 shares of the company’s stock valued at $448,000 after purchasing an additional 1,246 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Mirum Pharmaceuticals by 11.7% in the 1st quarter. Russell Investments Group Ltd. now owns 17,481 shares of the company’s stock valued at $439,000 after acquiring an additional 1,825 shares during the period. William Blair Investment Management LLC raised its position in shares of Mirum Pharmaceuticals by 0.9% in the 1st quarter. William Blair Investment Management LLC now owns 627,272 shares of the company’s stock worth $15,757,000 after acquiring an additional 5,494 shares in the last quarter. Affinity Asset Advisors LLC lifted its stake in shares of Mirum Pharmaceuticals by 220.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 160,000 shares of the company’s stock worth $4,019,000 after purchasing an additional 110,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Mirum Pharmaceuticals by 37.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock valued at $40,131,000 after purchasing an additional 432,824 shares in the last quarter.

Mirum Pharmaceuticals Price Performance

NASDAQ MIRM opened at $41.61 on Tuesday. The company has a market cap of $1.99 billion, a price-to-earnings ratio of -18.29 and a beta of 1.16. The company has a debt-to-equity ratio of 1.34, a current ratio of 3.28 and a quick ratio of 3.09. The stock’s fifty day moving average price is $39.93 and its 200 day moving average price is $35.49. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $45.23.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Evercore ISI boosted their target price on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Leerink Partners boosted their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $39.00 to $44.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Cantor Fitzgerald lifted their price target on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Friday, October 11th. Ten research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $56.82.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.